PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: ECON Corporate Services / InvestorIdeas.com™

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Researchers Demonstrate Safety Of Aethlon Hemopurifier - Aethlon Medical, Inc. (OTCBB: AEMD) today reported new data related to the safe use of the Hemopurifier™ treatment technology in animal studies.
Researchers Demonstrate Safety Of Aethlon Hemopurifier

 

NewswireToday - /newswire/ - San Diego, CA, United States, 2005/05/24 - Aethlon Medical, Inc. (OTCBB: AEMD) today reported new data related to the safe use of the Hemopurifier™ treatment technology in animal studies..

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

No Adverse Events in Animal Studies

Aethlon Medical, Inc. (OTCBB: AEMD) today reported new data related to the safe use of the Hemopurifier(TM) treatment technology in animal studies. Researchers documented that the Hemopurifier, which has been developed to treat individuals infected with HIV (the AIDS virus), Hepatitis-C (HCV), and bioweapon threats, including Smallpox, was able to treat for extended periods of time without any adverse events. Aethlon has previously published pre-clinical data related to the rapid clearance of HIV, HCV and Smallpox related viruses from human blood. Aethlon Chairman & CEO James A. Joyce stated, "The demonstration of safety in animals combined with our known ability to capture infectious agents from human blood provides further clarity to our vision of treating humans in a safe and effective manner."

The study involved a total of fifteen Hemopurifier treatment procedures that were performed on six different New Zealand white rabbits. Treatment times ranged from 45 minutes to five hours with an average treatment period of 2.9 hours in the study. Blood flow rates allowed for the entire blood system to circulate through the Hemopurifier every twenty minutes. In general, the animals tolerated the Hemopurifier treatment well and were able to move about freely within a restricted space. The most common interruption during the procedure was related to excessive animal movement that resulted in low arterial side pressures due to partial occlusion of the catheter. Such issues are not expected in human treatment. Blood studies of both a control dialysis cartridge and the Hemopurifier showed a general diminution of HCT, RBC and several other parameters except for Na+. In general, the control dialysis cartridge caused greater decreases in blood cells, metal ions and metabolites than did the Hemopurifier. Blood changes between the control dialysis cartridge and the Hemopurifier were a 32% vs. 20% decrease in thrombocytes and a 12% decrease vs. an 18% increase in leukocytes respectively. In every case, the observed blood chemistry changes were temporary and subsided prior to the next treatment. The attending veterinarian felt that exposure of the rabbits to antigens present in a companion animal dialysis clinic but not normally present in the rabbit hatchery (i.e. dogs, cats and other animals undergoing treatment) was the likely explanation for the increase in leukocyte levels. Regardless, no infections were ever observed. On two occasions, core body temperature rose from 102.2 to 105.2 degrees F during the Hemopurifier treatment. However, simply moving the rabbits from their cages to the treatment facility also produced similar temperature elevations up to 105 degrees F. Such data suggests that the temporary increase in temperature was not directly related to the Hemopurifier treatment. A decrease in thrombocytes is a common consequence associated with dialysis treatment. In conclusion, Aethlon researchers did not observe any adverse events during the Hemopurifier animal study. The choice to utilize rabbits in the study was related to the similarity in the infection pathogenesis of rabbit Pox with human Smallpox. As smallpox efficacy studies are not allowed in humans, related animal studies are the primary challenge for market approval as a treatment countermeasure. Aethlon Chief Scientific Officer Dr. Richard Tullis added, "I am very pleased with the results of this study. The rabbits, which are normally more fragile than other test species, have tolerated the Hemopurifier even better than we expected. Although the maximum treatment time was five hours, there is no reason to believe that the animals would not be able to tolerate much longer treatments. During the treatment they often sit up and investigate their surroundings."

About Aethlon Medical

Aethlon Medical is pioneering the development of viral filtration devices to treat drug and vaccine resistant pathogens. The market focus is the treatment of the Human Immunodeficiency Virus (HIV), Hepatitis-C (HCV), and Biological Weapon candidates. Aethlon has an experienced management team, which receives support and guidance from globally recognized science advisors representing the infectious disease, biowarfare and dialysis industries. Clinical Trials to treat HIV and HCV patients in India are scheduled to begin in the coming months, and U.S. clinical studies are expected to begin later this year.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

Source: Aethlon Medical, Inc.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: ECON Corporate Services / InvestorIdeas.com™

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services/Equipment articles,
CATCH Visitors via Your Competitors Announcements!


Researchers Demonstrate Safety Of Aethlon Hemopurifier

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Anne Hoversten 
858-459-7800
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any ECON Corporate Services / InvestorIdeas.com™ securities in any jurisdiction including any other companies listed or named in this release.

Medical Services/Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From ECON Corporate Services / InvestorIdeas.com™ / Company Profile


Read Medical Services/Equipment Most Recent Related Newswires:

Intubation Market Significant Profits Estimated to be Generated by 2025 Says Persistence Market Research
PMR Releases Report for Next Generation IV Infusion Pumps Market Impact of Existing and Emerging Market 2017-2025
Medical Tapes Market to Reach US$ 2Bn by 2024 Reports PMR
Global Pyrogen Testing Market Value Expected to Increase to US$ 1.37 Billion by 2024 Says PMR
Huber Needles Market Expected to Reach US$ 55M by 2024 According to PMR
ZOLL Technologies for Improving CPR Quality to be Showcased at NTI 2017
ConfirmMDx Improves Prostate Cancer Diagnosis in African American Men
Biomarker-based Technologies to Disrupt Conventional Diagnosis in Diabetes Management across the Globe Finds Frost & Sullivan
Agfa Specialty Products Announces the Launch of UNIQOAT
Sparta Releases Stratas 3.0 and TrackWise Intake
GE Healthcare Signs Agreement with HealthTrust to Supply Radiopharmaceuticals
GE Introduces CardioGraphe - The World’s First Dedicated Cardiovascular CT System
Frost & Sullivan Lauds ClearFlow’s ACT® Technology as a Transformational Force in Post-operative Cardiothoracic Surgery Protocols
ZOLL Receives Health Canada Approval for Two New Models of AEDS
ZOLL Hospital Wearable Defibrillator Receives Premarket Approval from the FDA

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Persistence Market Research (P) Ltd

Visit  MagLar, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)